Flow cytometry analysis (gating shown in Supporting Information Fig. S2a) of the three tumor phases revealed a strong upregulation of the early cell surface activation marker CD69 in BRAFi‐sensitive tumors on T cells, whereas NK cells displayed unchanged CD69 levels upon BRAFi therapy (Fig. 3a). This evidence concerns the gene CD69 and neoplasm.